The study was aimed to the evaluation the effect of
NO- synthase inducer
impaza on endothelial function and erectile function in patients undergoing
coronary artery bypass grafting (CABG). The study involved 127 men with stable
coronary artery disease (CAD), aged 55.8 +/- 5.3 years, which were planned on CABG. The survey included assessment of IIEF score and blood
lipid levels, registration of nocturnal penile tumescences, postcompression tests on the shoulder and cavernous arteries. Endothelial function was assessed as the plasma levels of
nitric oxide (NO) and
endothelin-1 (ET-1). The comparison group of patients (n = 67) were treated with standard rehabilitation program, and the study group (n = 67) additionally has received
impaza 1
tablet a day for 24 weeks. It is shown that in patients with
erectile dysfunction (ED) undergoing CABG, the use of
impaza for 24 weeks facilitates optimal dynamic expression of the ED. But a year after the operation, there were marked deterioration in erectile function, indicating a short-term effect of action of
impaza that may require its longer use. In addition, 6 months after CABG, patients receiving
impaza had better indicators of functional activity of the endothelium in shoulder and cavernous arteries compared with patients who received conventional rehabilitation; one year after surgery, however, there were no significant differences in these parameters. Restorative treatment using
impaza in CAD patients after
myocardial revascularization operations has positive influence on the NO, ET-1 levels, which is reflected in the functional state of the endothelium and characterized by an increase in
vasodilator properties and decrease in
vasoconstrictor properties.